BONESUPPORT extended its U.S. distribution agreement with Zimmer Biomet (ZBH), continuing ZBH’s exclusive rights for CERAMENT BONE VOID FILLER products for orthopaedics, trauma and foot/ankle indications.
CERAMENT received its initial FDA 510(k) clearance in 2005, and the original distribution agreement with Biomet was signed in 2012. Presently, BONESUPPORT is enrolling patients into the FORTIFY Clinical Study, an FDA-approved IDE randomized control pivotal study for CERAMENT G antibiotic eluting product.
Sources: BONESUPPORT AB; ORTHOWORLD Inc.
BONESUPPORT extended its U.S. distribution agreement with Zimmer Biomet (ZBH), continuing ZBH's exclusive rights for CERAMENT BONE VOID FILLER products for orthopaedics, trauma and foot/ankle indications.
CERAMENT received its initial FDA 510(k) clearance in 2005, and the original distribution agreement with Biomet was signed in 2012....
BONESUPPORT extended its U.S. distribution agreement with Zimmer Biomet (ZBH), continuing ZBH’s exclusive rights for CERAMENT BONE VOID FILLER products for orthopaedics, trauma and foot/ankle indications.
CERAMENT received its initial FDA 510(k) clearance in 2005, and the original distribution agreement with Biomet was signed in 2012. Presently, BONESUPPORT is enrolling patients into the FORTIFY Clinical Study, an FDA-approved IDE randomized control pivotal study for CERAMENT G antibiotic eluting product.
Sources: BONESUPPORT AB; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.